Renal and hepatic impairment studies have a distinct niche in drug development: they are critical, strictly controlled, and appear deceptively simple at first glance.
Image Credit: 4zevar/Shutterstock.com
Many sponsors view them as normal PK exercises, something to "slot in" once the program has reached a certain point. However, for the teams that do these investigations daily, the reality is significantly more difficult.
Years of experience at hVIVO's renal and hepatic impairment section have revealed a recurring pattern: sponsors generally underestimate the requirements of these studies, overestimate the speed of their delivery, and misunderstand the operational and clinical details that influence success.
Before we get into that, there is an even more fundamental question: Does the program require a specialized RI/HI study at all?
Sponsors may choose between physiologically based PK modeling (PBPK), population PK techniques, or a standalone renal or hepatic impairment research based on the medicine, its metabolism, indication, and available clinical and non-clinical data. It is vital to choose the correct course early on.
An incorrect assumption or a judgment made too late can result in needless regulatory delays at the moment of registration.
Here are the five most prevalent misconceptions, and what sponsors need to understand before designing or commissioning an impaired population study.
1. “These studies are straightforward.”
On paper, renal and hepatic impairment studies appear straightforward: clear standards, identified patient populations, and expected PK outcomes. But that simplicity is deceptive.
Recruitment is one of the most difficult challenges. Stable mild hepatic impairment individuals are uncommon in Western Europe, and severe cases are considerably more difficult to locate without specialized networks.
Renal impairment patients require access to all stages of CKD, dialysis, and experienced clinicians who understand the unique PK of the impaired group.
In truth, these studies only appear straightforward when the site has the appropriate subjects, clinicians, research design, and infrastructure. Without that basis, timelines lag, and data quality degrades.
2. “Any early‑phase unit can run these studies.”
Not all early-phase units are suited for impaired population research – far from it. With over 30 years of expertise in organizing and conducting RI/HI research, hVIVO's renal/hepatic unit operates with an integration level truly uncommon.
- Hepatology and nephrology specialists embedded in the workflow
- Rotating nephrologists from a university hospital
- Coss‑training between hospital and site staff
- Shared recruitment pathways
- Access to dialysis equipment
A strong clinical network is essential for ensuring consistent recruitment and high-quality data. Sponsors who believe that any Phase I unit can complete these trials often find too late that specialized infrastructure is the difference between a successful study and a stalled one.
3. “We already know what study design we need.”
Sponsors who are confident in their scientific reasoning may lack practical experience with compromised population studies.
One of the most common early mistakes occurs before design discussions begin: presuming that a standalone RI/HI trial is required when, in some situations, a waiver or other strategy (such as PBPK or population PK) may be appropriate.
Misinterpretation of rules often leads to last-minute demands. Sponsors may organize an RI/HI study right before registration because an authority requires data they thought they could avoid.
Once the need for a study is recognized, other design gaps frequently arise, including:
- Overlooking the matching strategy for the control group with normal renal or hepatic function
- Misunderstanding whether a single‑dose or multiple‑dose design is appropriate
- Underestimating PK variability in impaired populations
- Misinterpreting guideline allowances and restrictions
- Assuming unrealistic recruitment timelines
These issues come up regularly during protocol debates. The truth is, studies of the disabled population are specialized.
Early consultation with an experienced unit eliminates costly revisions and avoidable delays – and prompt preparation is critical because RI/HI studies are part of the registration package. When these judgments are made too late, they directly affect approval timelines.
4. “Quality is a given.”
Sponsors often believe that renal/hepatic investigations are common enough that quality "just happens." However, quality is the outcome of deliberate, continuous operational discipline. Over the last year, hViVO has modernized and enhanced its procedures by:
- Collaborating closely with regulators and QA
- Improving documentation pathways
- Tightening quality controls
- Redesigning workflows
These adjustments were not intended to increase the number of employees; rather, they were intended to improve work efficiency. Impaired population studies do not always yield high-quality results. It is designed using modern systems, rigorous methods, and continual improvement.
5. “Recruitment will be fast, right?”
Sponsors often ask the same three questions:
- Can you enroll eight patients per cohort?
- Can you do it in six months?
- Can you deliver this study?
The honest answer is that it depends on the population. Recruitment is influenced not only by the availability of patients with renal or hepatic impairment, but also by the inclusion and exclusion criteria that determine who is truly eligible.
Patients with severe impairment are rarely "healthy," thus developing clinically appropriate and operationally feasible criteria for both the impaired cohort and the matched control group is critical.
Renal impairment recruitment is feasible when a facility has a broad and active nephrology network, as hVIVO does.
Hepatic impairment is significantly more difficult, particularly in severe cases. Geography, hospital collaborations, patient stability, and clinical connections all affect timetables. Assuming consistent recruiting timetables across disability categories is one of the quickest ways to undermine a study design.
6. "We don’t need external expertise – we have got this."
This misperception produces the most friction. Some sponsors are confident that they know exactly what they require. Others understand that they require guidance. The distinction between the two becomes evident once protocol debates begin.
Studies with impaired populations require clinical judgment, operational nuance, regulatory knowledge, and a thorough understanding of impaired-population PK.
However, they require clarity on strategic questions that many early-stage teams have not had to answer before. Do we need an RI/HI study?
If so, should the design be full or reduced? Is there another option that would satisfy regulators? And, more importantly, when should the study be conducted – early enough to inform Phases 2 and 3, or closer to registration, when it becomes part of the approval package?
Most emerging teams cannot and should not make these decisions on their own. Seeking specialized expertise is not a weakness. The actual issue is presuming you do not need it, especially since the timing and design of RI/HI studies can directly impact regulatory outcomes.
The Bottom Line
Renal and hepatic impairment studies are not only a checklist. They are specialized clinical investigations requiring the appropriate patients, professionals, infrastructure, and operational discipline.
Sponsors who recognize this and work early with skilled teams prevent delays, reduce risk, and produce cleaner, more reliable data. Those who do not often learn the hard way.
Early-phase specialty ecosystems can have a significant effect. When clinical pharmacology, operations, laboratory science, and patient access are coordinated, the entire program moves more confidently and with fewer surprises, providing sponsors with the support they need to conduct these complex studies successfully.
Acknowledgments
Produced from materials originally authored by Maria Lehretz from hVIVO.
About hVIVO
hVIVO plc is a science‑led early‑phase drug development company purpose‑built to meet the growing complexity of modern clinical research. The Company operates an integrated early‑phase ecosystem that combines specialist clinical sites, advanced virology and immunology laboratories, human challenge expertise, and early drug development consulting. This unified model enables sponsors to generate rigorous, decision‑ready human data earlier in development, reducing uncertainty and accelerating progression through Phase I and II trials.
With industry‑leading capabilities in respiratory and infectious disease, alongside expanding expertise in cardiometabolic and other high‑growth therapeutic areas, hVIVO supports a diverse global client base that includes seven of the world’s ten largest biopharmaceutical companies. Its London quarantine facilities are the largest purpose‑built human challenge units in the world, complemented by additional early‑phase clinical capacity in Germany and a specialist consulting team providing strategic, regulatory, and biometry expertise.
The Company’s integrated approach delivers a seamless pathway from preclinical planning through early proof‑of‑concept, supported by continuous patient recruitment through FluCamp and a network of outpatient clinical sites for Phase II and III studies. By unifying scientific insight, operational control, and advanced laboratory capabilities, hVIVO provides sponsors with the clarity, speed, and reliability required to advance new medicines with confidence.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.